Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial-Reference-Cited by-同舟云学术

Pharmacological properties of faster-acting insulin aspart vs insulin aspart in patients with type 1 diabetes receiving continuous subcutaneous insulin infusion: A randomized, double-blind, crossover trial

Published:2016-11-14 Issue:2 Volume:19 Page:208-215
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Heise Tim¹,Zijlstra Eric¹,Nosek Leszek¹,Rikte Tord²,Haahr Hanne²

Affiliation:

1. Profil Institut für Stoffwechselforschung GmbH; Neuss Germany

2. Novo Nordisk A/S; Søborg Denmark

Funder

Novo Nordisk

Boehringer Ingelheim

Sanofi

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/dom.12803/fullpdf

Reference29 articles.

1. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes. Importance of postprandial glycemia to achieve target HbA1c levels;Woerle;Diabetes Res Clin Pract,2007

2. The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences;Home;Diabetes Obes Metab,2012

3. Insulin aspart in the management of diabetes mellitus: 15 years of clinical experience;Hermansen;Drugs,2016

4. Ultra-fast acting insulin analogues;Kalra;Recent Pat Endocr Metab Immune Drug Discov,2014

5. Ultrafast-acting insulins: state of the art;Heinemann;J Diabetes Sci Technol,2012

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep Deterministic Policy Gradient Control of Type 1 Diabetes;2024 European Control Conference (ECC);2024-06-25

2. Results of biosimilar assessing of insulin aspart preparations of Russian and foreign production using the hyperinsulinemic euglycemic clamp method and studying the use of a new ultra-fast-acting Russian biosimilar in pumps;Meditsinskiy sovet = Medical Council;2024-02-26

3. Study protocol for a randomised open-label clinical trial examining the safety and efficacy of the Android Artificial Pancreas System (AAPS) with advanced bolus-free features in adults with type 1 diabetes: the ‘CLOSE IT’ (Closed Loop Open SourcE In Type 1 diabetes) trial;BMJ Open;2024-02

4. Faster-acting insulin aspart versus insulin aspart in the treatment of type 1 or type 2 diabetes during pregnancy and post-delivery (CopenFast): an open-label, single-centre, randomised controlled trial;The Lancet Diabetes & Endocrinology;2023-11

5. Practical Aspects and Exercise Safety Benefits of Automated Insulin Delivery Systems in Type 1 Diabetes;Diabetes Spectrum;2023-05-01